Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bimagrumab - Eli Lilly and Company

Next Previous
X
Search
Drug Profile

Bimagrumab - Eli Lilly and Company

Alternative Names: BYM-338; LY-3985863

Latest Information Update: 13 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MorphoSys; Novartis
  • Developer Eli Lilly and Company; Novartis
  • Class Anti-inflammatories; Antihyperglycaemics; Monoclonal antibodies; Obesity therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inclusion body myositis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Obesity
  • Discontinued Cachexia; Inclusion body myositis; Muscular atrophy; Type 2 diabetes mellitus

Most Recent Events

  • 21 Oct 2024 Phase-II clinical trials in Obesity (Combination therapy) in USA (SC) (NCT06643728)
  • 21 Oct 2024 Phase-II clinical trials in Obesity (Monotherapy) in USA (SC) (NCT06643728)
  • 22 Mar 2024 Discontinued - Phase-II for Cachexia in Netherlands, Romania, Lithuania, Switzerland, Switzerland, United Kingdom, USA (IV) (Eli Lilly and Company pipeline, March 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top